219 related articles for article (PubMed ID: 29973280)
1. Pay-for-performance as a cost-effective implementation strategy: results from a cluster randomized trial.
Garner BR; Lwin AK; Strickler GK; Hunter BD; Shepard DS
Implement Sci; 2018 Jul; 13(1):92. PubMed ID: 29973280
[TBL] [Abstract][Full Text] [Related]
2. Using pay for performance to improve treatment implementation for adolescent substance use disorders: results from a cluster randomized trial.
Garner BR; Godley SH; Dennis ML; Hunter BD; Bair CM; Godley MD
Arch Pediatr Adolesc Med; 2012 Oct; 166(10):938-44. PubMed ID: 22893231
[TBL] [Abstract][Full Text] [Related]
3. Testing the incremental effectiveness of pay-for-performance to improve implementation of a motivational interviewing brief intervention for substance use disorders in HIV settings: Results of a cluster-randomized type 3 hybrid trial.
Garner BR; Tueller S; Bradshaw M; Speck K; Satre D; Rash C; Donohoe T; Mungo J; Philbrick S; Ruwala R; Roosa M; Zehner M; Ford J
Res Sq; 2023 Dec; ():. PubMed ID: 38196639
[TBL] [Abstract][Full Text] [Related]
4. The Reinforcing Therapist Performance (RTP) experiment: study protocol for a cluster randomized trial.
Garner BR; Godley SH; Dennis ML; Godley MD; Shepard DS
Implement Sci; 2010 Jan; 5():5. PubMed ID: 20205824
[TBL] [Abstract][Full Text] [Related]
5. Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?
Tan EC; Pwu RF; Chen DR; Yang MC
Qual Life Res; 2014 Mar; 23(2):687-96. PubMed ID: 23975377
[TBL] [Abstract][Full Text] [Related]
6. Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion.
Heslin M; Patel A; Stahl D; Gardner-Sood P; Mushore M; Smith S; Greenwood K; Onagbesan O; O'Brien C; Fung C; Ohlsen R; Hopkins D; Lowe P; Arbuthnot M; Mutatsa S; Todd G; Kolliakou A; Lally J; Stubbs B; Ismail K; David A; Murray R; Atakan Z; Gaughran F
BMC Psychiatry; 2017 Dec; 17(1):407. PubMed ID: 29273021
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of diabetes pay-for-performance incentive designs.
Hsieh HM; Tsai SL; Shin SJ; Mau LW; Chiu HC
Med Care; 2015 Feb; 53(2):106-15. PubMed ID: 25397966
[TBL] [Abstract][Full Text] [Related]
8. The implementation & sustainment facilitation (ISF) strategy: Cost and cost-effectiveness results from a 39-site cluster randomized trial integrating substance use services in community-based HIV service organizations.
Hinde JM; Garner BR; Watson CJ; Ramanan R; Ball EL; Tueller SJ
Implement Res Pract; 2022; 3():26334895221089266. PubMed ID: 37091108
[No Abstract] [Full Text] [Related]
9. Paying for performance to improve the delivery of health interventions in low- and middle-income countries.
Diaconu K; Falconer J; Verbel A; Fretheim A; Witter S
Cochrane Database Syst Rev; 2021 May; 5(5):CD007899. PubMed ID: 33951190
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. The impact of pay-for-performance on therapists' intentions to deliver high-quality treatment.
Garner BR; Godley SH; Bair CM
J Subst Abuse Treat; 2011 Jul; 41(1):97-103. PubMed ID: 21315539
[TBL] [Abstract][Full Text] [Related]
12. The implementation and sustainment facilitation strategy improved implementation effectiveness and intervention effectiveness: Results from a cluster-randomized, type 2 hybrid trial.
Garner BR; Gotham HJ; Chaple M; Martino S; Ford Ii JH; Roosa MR; Speck KJ; Vandersloot D; Bradshaw M; Ball EL; Toro AK; Griggs C; Tueller SJ
Implement Res Pract; 2020; 1():. PubMed ID: 36189179
[TBL] [Abstract][Full Text] [Related]
13. The Costs and Cost-effectiveness of Collaborative Care for Adolescents With Depression in Primary Care Settings: A Randomized Clinical Trial.
Wright DR; Haaland WL; Ludman E; McCauley E; Lindenbaum J; Richardson LP
JAMA Pediatr; 2016 Nov; 170(11):1048-1054. PubMed ID: 27654449
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of a Diabetes Pay-For-Performance Program in Diabetes Patients with Multiple Chronic Conditions.
Hsieh HM; Gu SM; Shin SJ; Kao HY; Lin YC; Chiu HC
PLoS One; 2015; 10(7):e0133163. PubMed ID: 26173086
[TBL] [Abstract][Full Text] [Related]
15. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients.
Hsieh HM; Lin MY; Chiu YW; Wu PH; Cheng LJ; Jian FS; Hsu CC; Hwang SJ
Nephrol Dial Transplant; 2017 Jul; 32(7):1184-1194. PubMed ID: 28486670
[TBL] [Abstract][Full Text] [Related]
17. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
18. Payment methods for outpatient care facilities.
Yuan B; He L; Meng Q; Jia L
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011153. PubMed ID: 28253540
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
